Sep 22, 2022 • 8:00 am EDT Corbus Presents First Pre-Clinical Data for CRB-913 at the European Association for the Study of Diabetes 2022 Annual Conference
Sep 12, 2022 • 7:00 am EDT Corbus Pharmaceuticals to Present Virtually at the H.C. Wainwright 24th Annual Global Investment Conference
Aug 9, 2022 • 8:00 am EDT Corbus Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
May 11, 2022 • 8:00 am EDT Corbus Presents Latest Preclinical Data for CRB-601 at the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference
May 10, 2022 • 8:00 am EDT Corbus Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Apr 8, 2022 • 1:05 pm EDT Corbus Presents First Preclinical Data for CRB-601 at the American Association for Cancer Research (AACR) Annual Meeting
Mar 11, 2022 • 8:05 am EST Corbus Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference
Mar 8, 2022 • 8:05 am EST Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Updates
Dec 7, 2021 • 8:05 am EST Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer